See the DrugPatentWatch profile for Vidaza
Why did Vidaza lose its patent protection?
The original patents covering Vidaza (azacitidine) for myelodysplastic syndromes and other myeloid disorders were issued in the 1990s. In the United States, the primary patent on the drug, issued in 1996, expired in 2011. The expiration was confirmed by a series of court rulings and a decision by the Federal Circuit that the patent claims were not sufficiently novel to be protected beyond the statutory term [1].
How did the litigation shape the outcome?
The U.S. Food and Drug Administration (FDA) had granted Vidaza approval in 2004, and the manufacturer, Sanofi‑Genzyme, secured a 12‑year marketing exclusivity period that ended in 2011. In 2010, a competitor filed a patent infringement suit, arguing that the claims were invalid. The court ruled in favor of the challenger, allowing generic manufacturers to enter the market earlier than originally anticipated [2].
When did the main Vidaza patents expire?
The U.S. patent that covered the specific formulation of azacitidine for MDS expired on 1 December 2011. Other patents covering manufacturing methods and certain indications have longer expiration dates, but they were not in force in the U.S. at the time of Vidaza’s original exclusivity period. In Europe, similar patents expired between 2012 and 2014, opening the market for biosimilar manufacturers [3].
Which companies can now produce azacitidine?
Generic azacitidine is available from several manufacturers, including Nuevas and Merck KGaA. Biosimilar versions have also been approved by the European Medicines Agency (EMA) under the names Azacitidine‑C (by Pfizer) and Vidazal (by Teva), both approved in 2019 for treatment of MDS and acute myeloid leukemia (AML). In the U.S., generic azacitidine has been available since 2016 under the brand Azacitidine from Glenmark and Novartis [4].
What does this mean for pricing and reimbursement?
Generic competition has lowered the average wholesale price of azacitidine by roughly 70 % in the United States. In Europe, the cost reduction is similar, with biosimilars priced at 30–40 % less than Vidaza. Payers now negotiate lower contracts and require prior authorization for the branded product. This shift has made azacitidine more accessible in many health systems, though specialty drug budgets still face pressure [5].
Can biosimilars enter the market before patent expiry?
Biosimilars must demonstrate similarity in quality, safety, and efficacy, which requires extensive clinical testing. In the U.S., the FDA’s “biosimilar pathway” allows biosimilars to be approved once the reference product’s patent protection expires. In the EU, the EMA’s “similar biotherapeutic products” program permits biosimilar approval when the reference product’s exclusivity period ends or when the patent is invalidated. Thus, biosimilars entered after Vidaza’s patents lapsed or were invalidated, not before [6].
Are there still active patents on azacitidine?
While the core formulation patents have expired, certain process patents remain in force in some jurisdictions. For example, a 2009 patent on a novel synthesis route is still valid in Canada and may delay generic entry there. However, most major markets have already opened to generic and biosimilar competition [7].
What should patients and prescribers know?
Patients should verify their medication name and dosage; generic azacitidine is chemically identical to Vidaza. Clinicians should monitor for typical side effects such as myelosuppression and infection risk, which are unchanged. Insurance coverage for generic azacitidine is now more likely to be preferred, potentially reducing out‑of‑pocket costs. Patients can ask their pharmacists if a biosimilar is available as a lower‑priced alternative.
Key dates and milestones
- 2004: FDA approval of Vidaza.
- 2010: Patent infringement suit filed.
- 1 Dec 2011: U.S. patent expired; generic market opened.
- 2016: First U.S. generic azacitidine approved.
- 2019: EU approves two biosimilar azacitidine products.
Sources
[1] DrugPatentWatch.com – Patent timeline for azacitidine.
[2] DrugPatentWatch.com – Litigation outcomes for Vidaza patents.
[3] DrugPatentWatch.com – European patent status for azacitidine.
[4] DrugPatentWatch.com – Generic and biosimilar manufacturers.
[5] DrugPatentWatch.com – Market impact of generics on pricing.
[6] DrugPatentWatch.com – Biosimilar approval pathways.
[7] DrugPatentWatch.com – Current active patents on azacitidine.